Baidu
map

脑白质脱髓鞘病变的影像诊断5分钟学会:

2022-11-08 ANDs 华夏影像诊断中心

脑白质脱髓鞘病变的影像诊断。

脑白质脱髓鞘病变的影像诊断

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2115474, encodeId=7aa221154e4eb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9bc8436692, createdName=ms2000001558856228, createdTime=Mon Feb 20 09:05:22 CST 2023, time=2023-02-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2099209, encodeId=a3da209920909, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989e6529928, createdName=ms4000000052884687, createdTime=Tue Nov 08 16:14:17 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099185, encodeId=ad3a20991859b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Tue Nov 08 14:28:24 CST 2022, time=2022-11-08, status=1, ipAttribution=)]
    2023-02-20 ms2000001558856228 来自四川省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2115474, encodeId=7aa221154e4eb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9bc8436692, createdName=ms2000001558856228, createdTime=Mon Feb 20 09:05:22 CST 2023, time=2023-02-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2099209, encodeId=a3da209920909, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989e6529928, createdName=ms4000000052884687, createdTime=Tue Nov 08 16:14:17 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099185, encodeId=ad3a20991859b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Tue Nov 08 14:28:24 CST 2022, time=2022-11-08, status=1, ipAttribution=)]
    2022-11-08 ms4000000052884687

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2115474, encodeId=7aa221154e4eb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9bc8436692, createdName=ms2000001558856228, createdTime=Mon Feb 20 09:05:22 CST 2023, time=2023-02-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2099209, encodeId=a3da209920909, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989e6529928, createdName=ms4000000052884687, createdTime=Tue Nov 08 16:14:17 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099185, encodeId=ad3a20991859b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Tue Nov 08 14:28:24 CST 2022, time=2022-11-08, status=1, ipAttribution=)]
    2022-11-08 ms5000001410456216

    学习了

    0

相关资讯

JNNP:芬戈莫德停药后多发性硬化复发临床分析

Fingolimod是2010年欧洲批准的首个用于缓解复发性多发性硬化(RRMS)的疾病修饰疗法(DMT)。 在体内,fingolimod被磷酸化形成fingolimod磷酸盐,类似于天然存在的鞘氨醇

JNNP:脊髓损伤和脑灰质萎缩独立预测明确的多发性硬化症的临床恶化,一项为期5年的多中心研究

多发性硬化(MS)是一种炎症、脱髓鞘和神经退行性中枢神经系统(CNS)疾病,具有异质性演变和临床/影像学特征。尽管多发性硬化症的病理特征是局部脱髓鞘病变的积累,但也会发生脑和脊髓神经变性。鉴于多发性硬

JNNP:处方类阿片药物在多发性硬化症中的应用

疼痛可能是多发性硬化(MS)最严重的症状之一。抑郁和焦虑,可能会影响多发性硬化的严重程度和影响。当神经性疼痛治疗无效时,可向MS患者开具用于慢性非癌症疼痛的阿片类药物。考虑到阿片类药物使用的潜在危害以

JNNP:儿童多发性硬化症残疾的早期预测因素

多发性硬化(MS)在儿童中相对罕见,发病率为0.13至0.66/100 000名儿童。在儿童中,其临床病程是高度炎症性的,并经常恶化(复发),特别是在症状出现后的最初几年。儿科发病的多发

MRI显示白质静脉密度降低与老年人的神经退行性变和认知障碍有关

由于阿尔茨海默病 (AD) 和相关痴呆症的增加,与年龄相关的认知和功能衰退越来越普遍。在不同类型的痴呆症中报告了不同程度和模式的脑萎缩,

CONNECT临床试验:对于儿童多发性硬化症,富马酸二甲酯vs干扰素β-1a哪家强?结果来了!

JAMA Netw Open:富马酸二甲酯vs β-1a干扰素在儿童起病多发性硬化患者中的作用——CONNECT随机临床试验

Baidu
map
Baidu
map
Baidu
map